



**Media Contact:**  
**Jonathan Black**  
**JDP THERAPEUTICS, INC.**  
**Email: [info@jdptherapeutics.com](mailto:info@jdptherapeutics.com)**  
**[www.jdptherapeutics.com](http://www.jdptherapeutics.com)**

## **European and Australian Patent Issuance to Extend Products' Global Protection**

**BLUE BELL, PENNSYLVANIA, March 28, 2017** – JDP Therapeutics Inc., a privately held specialty pharmaceutical company focused on developing and commercializing proprietary product candidates principally for use in the hospital and urgent care settings, announced today that the EUROPEAN and AUSTRALIAN PATENT OFFICES have granted the issuance of JDP's patents covering the company's lead products in their territories.

European Patent Office granted the issuance of JDP's new patent, **EP 2 477 634 B1** (application # 10794820.0), covering JDP's lead products JDP-205, JDP-207, and other related products, titled "Non-sedating antihistamine injection formulations and method of use thereof".

Australian Patent Office has issued the Certificate of Grant to JDP's new AU patent: **AU 2010 266103 B2**, covering JDP-205, JDP-207, and other related products, titled "Non-sedating antihistamine injection formulations and method of use thereof".

The newly issued patents in Europe and Australia further expand the intellectual property portfolio in new territories for the company's lead assets, which are currently in pivotal Phase 3 clinical trials in N. America. The two international patents claim new methods of use of JDP's lead product JDP-205 and JDP-207 for the treatment of acute urticaria, the most common symptom of acute allergic reactions.

### **About JDP-205 (IV Cetirizine)**

JDP-205 is a proprietary injectable product of cetirizine (IV Cetirizine) being developed for the treatment of acute urticaria, the most common symptom of acute allergic reactions, for the hospital, urgent care, and clinic markets. Due to the acute nature of this disease, an injectable product is needed to provide an immediate onset of action.

A market QUANT study surveyed 110 physicians and revealed that 86% of responding doctors had indicated readiness to use JDP-205 (IV Cetirizine) in place of the current therapy (diphenhydramine injection). Physicians cited JDP-205's lack of side effects as compared to those associated with diphenhydramine as the most compelling reason underlying their support for the JDP-205 treatment.

Two additional independent market research studies with in-depth clinician interviews confirmed the findings that IV Cetirizine will be able to fulfill the unmet need of the current therapy.

Acute urticaria is the most common symptom of acute allergic reaction, a serious and potentially life-threatening condition which has been growing at concerning rates with very limited options for treatment. JDP-205 (IV Cetirizine) will offer a superior treatment to the current therapy for the first time in the last 60+ years.

### **About JDP Therapeutics Inc.**

JDP Therapeutics Inc., a privately held specialty pharmaceutical company focused on developing and commercializing proprietary product candidates principally for use in the hospital and urgent care settings. Its lead product candidate is now at the last stage of phase 3 development for acute urticaria (acute allergic reactions) for the hospital, urgent care center and clinic markets.

JDP Therapeutics focuses on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use in the hospital and clinical setting. The company develops unique dosage forms, novel formulations, and new indications for proven chemical entities to achieve their full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information about JDP, please email: [info@idptherapeutics.com](mailto:info@idptherapeutics.com)

###

#### *Safe Harbor Statement Regarding Forward-looking Statements*

*The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.*